Evidence map›Paper›PMID 40119338›Full record

ArticleBMC public health2025

Estimating the cost of and willingness to pay for providing the dapivirine ring for HIV prevention in Kenya.

Peter Stegman, Steven Forsythe, Urbanus Kioko, Millicent Kiruki, Patriciah Jeckonia, Martha Larson, Delivette Castor, Guy Mahiane, Maryline Mireku, Mike Ekisa and 4 more

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Peter StegmanAvenir Health, Glastonbury, CT, USA.
Steven ForsytheAvenir Health, Glastonbury, CT, USA. steven.forsythe@gmail.com.
Urbanus KiokoUniversity of Nairobi, Nairobi, Kenya.
Millicent KirukiLVCT Health, Nairobi, Kenya.
Patriciah JeckoniaLVCT Health, Nairobi, Kenya.
Martha LarsonFHI 360, Washington, DC, USA.
Delivette CastorColumbia University, New York, NY, USA.
Guy MahianeAvenir Health, Glastonbury, CT, USA.
Maryline MirekuLVCT Health, Nairobi, Kenya.
Mike EkisaNational AIDS and STI Control Programme, Nairobi, Kenya.
Kristine TorjesenFHI 360, Washington, DC, USA.
Mary MugambiNational AIDS and STI Control Programme, Nairobi, Kenya.
Daniel WereJhpiego, Nairobi, Kenya.
Katharine KripkeAvenir Health, Glastonbury, CT, USA.

Funding

Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
NIAID NIH HHS UM1 AI069470
6 · The paper itself

Abstract

backgroundAs Kenya prepared to introduce the PrEP ring (a long-acting product used by women for HIV prevention), the need to understand the resources required became increasingly important. The aim of this study was to determine the costs and preferences of potential ring clients by conducting a normative cost analysis and a contingent valuation study (In the context of willingness to pay literature, "preference" is used to refer to an interest in a service or product with specified benefits).

methodsThe study incorporates two parts: 1) a normative costing to estimate potential costs of providing the PrEP ring and 2) a willingness to use/pay assessment to evaluate client preference for the PrEP ring. Oral PrEP program managers from 12 facilities were interviewed to assess the direct and indirect resources required to deliver PrEP ring services. 539 women were interviewed (including both younger and older women, as well as female sex workers) using a questionnaire to assess the strength of the expressed interest in PrEP ring use, as reflected by their contingent valuation of the product. Women were presented with payment cards from which they selected the most they would be willing to pay. The primary outcomes of the study were: 1) the annual cost of PrEP ring use and 2) the average willingness to pay for the PrEP ring. Women in the willingness to pay component were selected, using a convenience sample, with approximately equal numbers of oral PrEP users and clients from other health services.

resultsThe cost to provide a full year of PrEP ring was US$206; 76% (US$156) of that cost was attributed to the PrEP rings. Of the respondents, 78% indicated some interest in using the PrEP ring; among those interested, 83% indicated some willingness to pay for it. Single women and women currently using oral PrEP expressed more interest in using the ring than women who were married or were not currently oral PrEP users. The median willingness to pay per visit was US$1.86.

conclusionsThis analysis revealed that costs are predominantly driven by commodities. Attempts to further reduce the cost of the commodities could significantly reduce the overall cost of PrEP ring service. Approximately half the women were willing to pay up to US$2 per month for the PrEP ring. Since the demand for the PrEP ring appears to be higher among current oral PrEP users compared to non-users, women who have initiated oral PrEP but who are unable or unwilling to continue may be good candidates for PrEP ring use. The annual willingness to pay for the PrEP ring (US$11.16) was significantly lower than the ring's cost ($206 per year), which suggests that attempts to fully recover costs would present a significant barrier for Kenyan women and would minimize societal benefits.

Indexed as

Anti-HIV AgentsContraceptive Devices, FemaleHIV InfectionsPre-Exposure ProphylaxisPyrimidinesAdolescentAdultCosts and Cost AnalysisFemaleHumansInterviews as TopicKenyaMiddle AgedSurveys and QuestionnairesYoung AdultAnti-HIV AgentsDapivirinePyrimidinesContingent valuationCostHIV preventionPrEPPrEP ringWillingness to pay

Identifiers

PMID40119338
PMCPMC11929272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.